CLL | Tumor

Allogeneic Hematopoietic Stem Cell Transplant Effective for Patients with CLL Previously Treated with Novel Agents

September 3rd 2020

Allogeneic hematopoietic stem cell transplant’s role in the chronic lymphocytic leukemia has changed due to new novel agents, but research shows its still effective despite novel agent exposure.

Copiktra Plus Chemotherapy Needs Further Study of Toxicities in Patients With CLL

September 2nd 2020

An early phase 1b/2 study of Copiktra in combination of standard of care shows how the treatment is active for patients with chronic lymphocytic leukemia but further study is needed to ensure it is an effective and safe alternative to standard of care.

Arzerra Will Be Available at No Cost to Patients with Chronic Lymphocytic Leukemia in US

August 29th 2020

Arzerra will be available at no cost to patients via an oncology patient access program which will be facilitated through Patient Access Novartis Oncology.

Joining a Chronic Lymphocytic Leukemia Trial

August 25th 2020

Living with CLL as a Chronic Disease

August 25th 2020

The Future of Frontline Therapy in CLL

August 25th 2020

Understanding the Basics of Chronic Lymphocytic Leukemia

August 25th 2020

'Alexa For Health Care': New Virtual Assistant Helps Patients with Cancer at Home

August 8th 2020

WellBe, a new voice-enabled virtual assistant, can remind patients with cancer to take their medication and keep them on track from the comfort of their own home.

Venclexta-Gazyva Combo Creates More Long-Term Treatment Options for Patients with CLL

August 5th 2020

Dr. Othman Al-Sawaf discusses the encouraging long-term data that makes the Venclexta-Gazyva combination a viable treatment option for patients with CLL.

Follow-Up Data Confirm Support for Use of Calquence in Patients with Relapsed/Refractory CLL, Expert Says

August 5th 2020

“Final results from ASCEND confirm the findings of the interim analysis and support the favorable efficacy and safety of (Calquence) versus standard-of-care regimens in relapsed or refractory CLL,” said Dr. Paolo Ghia.

Brukinsa May Cause Fewer Side Effects Than Other BTK Inhibitors for Patients with B-Cell Malignancies

August 5th 2020

A clinical trial of Brukinsa (zanubrutinib) is open to patients with B-cell blood cancers and will determine whether the side effects re-emerge with Brukinsa.

CURE's Clinical Trial Corner: July 2020

July 30th 2020

A list of the recent trial initiations that occurred within the cancer space in July.

3 Drug Treatment Puts Some Patients With CLL On the Road to Remission

July 21st 2020

A three-drug treatment sparked complete responses in more than half of patients with high-risk chronic lymphocytic leukemia, who also tolerated the regimen well.

The Importance of More Thoughtful Treatment Strategies in High-Risk CLL

July 2nd 2020

“If I only have one tool to treat the disease, I will play with that tool in many different ways. But if I have access to four different tools, then I will give up tool (number) one if I don't feel it's working,” explained Dr. Mazyar Shadman of the Seattle Cancer Care Alliance, about his approach to treating high-risk chronic lymphocytic leukemia in an interview with CURE®.

Expert Breaks Down the Three Treatment Modalities Currently Being Investigated in CLL

June 30th 2020

“There’s a lot of work to do in CLL,” said Dr. Mazyar Shadman about the treatments currently being investigated in CLL. “We have been very fortunate to be able to provide a lot of options to our patients, but we shouldn't forget that there's a long way to go.”

Expert Advises Patients with CLL on Three Things They Should Be Aware of To Maximize the Benefit of Upfront Treatment

June 29th 2020

In an interview with CURE®, Dr. Mazyar Shadman discussed ways that patients with chronic lymphocytic leukemia can play a role in ensuring that they are able to reap the benefits of treatment.

Conversations Between Patient and Oncologist Are Important in Avoiding 'Common Mistake' When Treating CLL

June 27th 2020

In an interview with CURE®, Dr. Mazyar Shadman discussed the enormous variety of treatment preferences among patients with CLL and said that emphasis should be placed on treating each person according to their wishes.

What Factors Play a Role in Determining Optimal First Line Treatment for Patients With CLL

June 26th 2020

There are three things that should be considered when deciding what is the optimal treatment in the first line setting for patients with chronic lymphocytic leukemia (CLL), according to Dr. Mazyar Shadman.

CURE's Clinical Trial Corner: June 2020

June 25th 2020

Here is a list of the recent trial initiations that occurred within the cancer space in June.

The Best Policy to Eliminate Barriers to Care

June 23rd 2020

Regulation changes could eliminate barriers to potentially lifesaving CAR-T cell immunotherapy for patients covered by Medicare or Medicaid.

Child Dressed as Captain America Rings Bell to Celebrate Finishing Cancer Treatment, University of Iowa Health Care Professor Looks to Expand Access to Test that Can Detect Traces of Cancer in DNA, and More

June 19th 2020

From a study showing a popular cancer side effect management steroid decreasing the risk of death for patients in the hospital with COVID-19 to a new liquid biopsy test detecting lingering cancer in DNA, here’s what’s making the headlines in the cancer space this week.

The Latest News and Updates in Chronic Lymphocytic Leukemia

June 8th 2020

Here is a roundup of the latest news and updates for patients with Chronic Lymphocytic Leukemia from CURE.

Long-Term Data Support Use of Venclexta-Gazyva in Patients With Previously Untreated Chronic Lymphocytic Leukemia

June 5th 2020

“The superior efficacy of venetoclax-obinutuzumab has been observed and maintained in the current follow up,” Dr. Othman Al-Sawaf, of University Hospital of Cologne in Germany, said during a pre-recording presentation at the 2020 ASCO Virtual Scientific Program.

Calquence Shows Favorable Long-Term Outcomes in Treatment-Naive Chronic Lymphocytic Leukemia

June 4th 2020

“Collectively, these results support acalabrutinib (Calquence) use in upfront CLL,” said Dr. John C. Byrd. “This is compounded and supported by two additional phase III studies that have been completed with this agent.”

Novel Combination Therapy Shows Exciting Results in Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma

June 3rd 2020

Results from an early-phase trial showed that cirmtuzumab plus Imbruvica is safe and efficacious in treating patients with relapsed/refractory MCL and CLL.

Infection Risks, Impact of COVID-19 in Stem Cell Transplants for Blood Cancers

May 12th 2020

In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients,” Dr. Farukh Awan addressed concerns about the possibility of developing COVID-19 or any infection after a stem cell transplant to treat a blood cancer.

Blood Cancer Therapies May Play a Role in Treating COVID-19

May 7th 2020

In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients,” Drs. Zainab Shahid, Farukh Awan and Ian Flinn addressed clinical trials that are underway to assess therapeutic approaches to COVID-19, including what role BTK inhibitors might play in treating the virus.

One Cancer Organization's Observations on the Impact of COVID-19 on the Blood Cancer Community

May 6th 2020

In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Lee Greenberger addresses steps that the Leukemia and Lymphoma Society have taken to help patients with blood cancer during the COVID-19 pandemic.

How Patients With Blood Cancers Can Boost Immune Systems to Fight Infections Like COVID-19

May 6th 2020

In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients,” Drs. Ian Flinn and Farrukh Awan addressed what patients with blood cancers could do to help boost their immune systems to help prevent infections such as COVID-19, and the risk for patients who are several years removed from receiving a stem cell transplant.

Chronic Lymphocytic Leukemia

May 6th 2020

Understanding chronic lymphocytic leukemia.